Literature DB >> 2793380

Phase II trial of PCNU in breast carcinoma.

J M Rubins1, S G Taylor.   

Abstract

The Eastern Cooperative Oncology Group undertook a limited institution phase II study of PCNU in advanced, metastatic breast cancer. The study was limited to patients treated with 1 to 2 prior chemotherapy regimens. Accrual goals were 30 patients but the study was terminated after 10 patients had no response, with a rapid time to progression of 4 weeks, despite considerable hematologic toxicity. Based on this experience and negative results in two prior studies in more heavily pretreated patients, we conclude PCNU is inactive in breast cancer.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2793380     DOI： 10.1007/bf00170866

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  5 in total

1.  Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors.

Authors:  V A Levin; P Kabra
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

2.  Interrelationships of some chemical, physicochemical, and biological activities of several 1-(2-haloethyl)-1-nitrosoureas.

Authors:  G P Wheeler; B J Bowdon; J A Grimsley; H H Lloyd
Journal:  Cancer Res       Date:  1974-01       Impact factor: 12.701

3.  PCNU in advanced breast cancer.

Authors:  S Martino; B A Samal; A Singhakowinta
Journal:  Cancer Treat Rep       Date:  1983-03

4.  Phase II trail of PCNU in refractory advanced breast cancer.

Authors:  J J Kavanagh; H Y Yap; G R Blumenschein; D Stewart; G P Bodey
Journal:  Am J Clin Oncol       Date:  1982-06       Impact factor: 2.339

5.  Inhibition of solid tumors by nitrosoureas. 1. Lewis lung carcinoma.

Authors:  J A Montgomery; G S McCaleb; T P Johnston; J G Mayo; W R Laster
Journal:  J Med Chem       Date:  1977-02       Impact factor: 7.446
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.